Co-Diagnostics Total Liabilities and Share Holders Equity 2017-2024 | CODX
Co-Diagnostics total liabilities and share holders equity from 2017 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
| Co-Diagnostics Annual Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2023 | $95 |
| 2022 | $123 |
| 2021 | $160 |
| 2020 | $71 |
| 2019 | $2 |
| 2018 | $2 |
| 2017 | $5 |
| 2016 | $1 |
| Co-Diagnostics Quarterly Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2024-09-30 | $72 |
| 2024-06-30 | $81 |
| 2024-03-31 | $87 |
| 2023-12-31 | $95 |
| 2023-09-30 | $109 |
| 2023-06-30 | $113 |
| 2023-03-31 | $117 |
| 2022-12-31 | $123 |
| 2022-09-30 | $148 |
| 2022-06-30 | $161 |
| 2022-03-31 | $171 |
| 2021-12-31 | $160 |
| 2021-09-30 | $105 |
| 2021-06-30 | $93 |
| 2021-03-31 | $81 |
| 2020-12-31 | $71 |
| 2020-09-30 | $55 |
| 2020-06-30 | $39 |
| 2020-03-31 | $20 |
| 2019-12-31 | $2 |
| 2019-09-30 | $4 |
| 2019-06-30 | $5 |
| 2019-03-31 | $6 |
| 2018-12-31 | $2 |
| 2018-09-30 | $3 |
| 2018-06-30 | $2 |
| 2018-03-31 | $3 |
| 2017-12-31 | $5 |
| 2017-09-30 | $6 |
| 2017-06-30 | $0 |
| 2017-03-31 | $0 |
| 2016-12-31 | |
| 2016-09-30 | $0 |
| 2016-06-30 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.027B | $0.007B |
| Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics Inc. is based in UT, United States. | |||